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ABSTRACT 46 
A two-compartment pharmacokinetic population model of anidulafungin was fitted to PK data 47 
from 23 critically-ill patients (age 65 (range 28-81 years), total body weight (TBW): 75 (range 54-48 
168) kg). TBW was associated with clearance and was incorporated into a final population PK 49 
model. Simulations suggested patients with higher TBW had less extensive MIC coverage.  Dosage 50 
escalation may be warranted in patients with high TBW to ensure optimal drug exposures for 51 
treatment of both C. albicans and C. glabrata. 52 
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The 2009 Infectious Diseases Society of America treatment guidelines for candidemia 71 
recommend the use of an echinocandin as initial therapy for critically ill patients (1).   72 
Anidulafungin is commonly used for the treatment of diseases caused by Candida spp. in critically 73 
ill patients.  However, there are relatively limited population pharmacokinetic data for this patient 74 
population (1-3).  A deep understanding of PK/PD relationships underpins the design of safe and 75 
effective regimens and highlights those circumstances where a standard fixed regimen may fail.  76 
Herein, we describe the population PK of anidulafungin in critically ill patients and evaluate the 77 
probability of achieving target AUC0-24h/MIC values at steady state against C. albicans and C. 78 
glabrata with the currently licensed regimen.  79 
A total of 23 critically ill patients with proven or suspected invasive fungal infection (from 80 
Hospital del Mar, Barcelona, Spain) receiving anidulafungin were recruited.  The study was 81 
approved by the Ethics Committee of Parc de Salut Mar (2016/6987/I) in Barcelona, Spain and 82 
written informed consent was obtained from patients or their legal representative before 83 
enrollment. 84 
All patients received a loading dose of 200 mg of anidulafungin (Ecalta ®) followed by a 85 
maintenance dosage of 100 mg/24h infused over 1 hour.  Sampling occurred after the 3
rd
 day of 86 
treatment and blood was collected pre-infusion and 1, 3, 5, 8, 18 and 24 h post administration in the 87 
majority of the patients.  Anidulafungin concentrations were measured using a previously described 88 
validated HPLC method (3) . 89 
 Population pharmacokinetic modelling was performed using Pmetrics (4, 5).  One and two-90 
compartment models were fitted to the data.  The elimination from the central compartment and 91 
intercompartmental distribution were modeled as first-order processes.  Age, gender, TBW, 92 
APACHE score and liver cirrhosis were evaluated as covariates using stepwise linear regression.  93 
Potential covariates were separately entered into the model and retained if their inclusion resulted 94 
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in a statistically significant improvement in the log likelihood value and/or improvements in the 95 
observed-predicted plots. 96 
The fit of each model to the data was assessed using a linear regression of observed-97 
predicted values both before and after the Bayesian step.  The mean prediction error and the mean 98 
bias-adjusted squared prediction error were used to assess bias and imprecision, respectively.  99 
Models were compared by calculating twice the difference in log likelihood values, which was then 100 
assessed against a Chi-square distribution using the appropriate degrees of freedom (i.e. difference 101 
in number of parameters for each model).  To further assess the predictive accuracy of the final 102 
model, a visual predictive check (VPC) was performed.   103 
Monte Carlo simulations (n=1000) of plasma concentrations were employed to calculate the 104 
AUC0-24/MIC at steady state (i.e. from 144-168 hours post treatment initiation). From the 1000 105 
simulated concentration–time profiles, a probability of target attainment (PTA) against C. albicans 106 
and C. glabrata was calculated using a free AUC0-24/MIC target of 20 and 7, respectively.  These 107 
targets have been associated with the stasis endpoint  using a preclinical model of disseminated 108 
candidiasis using CLSI methodology (6). A range of MIC values (0.002-16 mg/L) and a range of 109 
TBWs (70 and 150 kg) were examined.  Human protein binding of 99% was used to estimate free 110 
drug concentrations (7).  111 
The demographics of the study population were as follows: a total of 10 patients (43.5%) 112 
were male; the median (range) age was 65 (28-81) years; the total body weight (range) was 75 (54-113 
168) kg and the median APACHE severity score (range) was 21 (10-48).  Nine patients (39.1%) 114 
had liver cirrhosis with a Child Pugh score of A (n=1), B (n=3) and C (n=5). The median (range) of 115 
the estimated AUC0-24h were 102.19 (51.22-185.64) mg*h/L. The concentration–time profiles of 116 
anidulafungin in patients are shown in Figure 1. 117 
Estimates for central tendency, dispersion and 95% credibility limits for the population PK 118 
parameters are shown in Table 1. Total body weight (TBW) was the only covariate that explained 119 
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any portion of the observed variance.  In the final model, the clearance (CL) of anidulafungin was 120 
described using a power function (CL=CL1* (TBW/70)**0.75).  Figure 2 shows the observed-121 
predicted values before and after the Bayesian step.  After maximum a posteriori probability 122 
(MAP)-Bayesian estimation, the observed-versus-predicted plot had an intercept and slope of 0.099 123 
and 0.934, respectively and an r
2
 = 0.734. The bias and imprecision were both acceptable (bias = 124 
0.0729 mg/liter and imprecision, 0.982 mg/liter).  The predictive value of the model was further 125 
confirmed using a VPC plot (Figure 3). 126 
 Patients with larger TBW receiving a standard dosage of anidulafungin developed less drug 127 
exposure than smaller patients.  The difference in predicted MIC coverage between patients 128 
weighing 70 and 150 kg was a single MIC dilution.  For C. albicans a PTA ≥ 90% was achieved 129 
for patients with TBW ≤ 70 kg for C. albicans isolates with MIC values ≤ 0.032 mg/L.  For heavier 130 
patients the coverage of C. albicans MIC was not as extensive and high PTAs were only achieved 131 
for isolates with MIC values ≤ 0.016 mg/L.  This difference was mitigated by an increase in 132 
maintenance dosage to 150 mg/day in heavier patients (data not shown).  For C. glabrata a PTA ≥ 133 
90% could be achieved for MIC values ≤ 0.064 mg/L for patients with a TBW up to 150 kg 134 
receiving the standard anidulafungin dosage (Figure 4).  When the same dosage increase was 135 
simulated, a PTA ≥ 90% could be achieved for MIC values ≤ 0.125 mg/L and ≤ 0.064 mg/L for 136 
patients with a TBW of 70 kg and 150 kg, respectively (data not shown). 137 
The finding that total body weight had an influence on anidulafungin clearance is consistent 138 
with a significant body of evidence supporting this observation for the echinocandin class in 139 
general (1, 9-11).  Both linear and exponential relationships have been used to describe the effect 140 
of weight on clearance (10).  Regardless of the function that is ultimately used, heavier patients 141 
require progressively higher absolute dosages to achieve comparable drug exposures to those 142 
observed in smaller patients.  For both C. albicans and C. glabrata, a TBW of 150 kg resulted in 143 
the loss of an MIC dilution that can be covered using the current licensed regimen compared with 144 
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70 kg patients.  Critically ill patients with high TBW may require higher dosages of anidulafungin 145 
for the treatment of C. albicans or C. glabrata infections to avoid potential clinical failures.  146 
Further prospectively conducted studies are warranted. 147 
ACKNOWLEDGMENTS 148 
None to declare 149 
  150 
 8 
REFERENCES 151 
1.  Pappas PG, Kauffman CA, Andes D, Benjamin, Jr. DK, Calandra TF, Edwards, Jr. JE, Filler 152 
SG, Fisher JF, Kullberg B, Ostrosky‐Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, 153 
Infectious Diseases Society of America. 2009. Clinical Practice Guidelines for the 154 
Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. 155 
Clin Infect Dis 48:503–535. 156 
2.  Liu P. 2013. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in 157 
adult patients with fungal infections. Antimicrob Agents Chemother 57:466–474. 158 
3.  Martens-Lobenhoffer J, Rupprecht V, Bode-Böger SM. 2011. Determination of micafungin 159 
and anidulafungin in human plasma: UV- or mass spectrometric quantification? J 160 
Chromatogr B 879:2051–2056. 161 
4.  Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary 162 
R, Chubatiuk A, Schumitzky A. 2013. Two general methods for population pharmacokinetic 163 
modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet 164 
Pharmacodyn 40:189–99. 165 
5.  Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate 166 
detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric 167 
pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467–76. 168 
6.  Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. 2010. In vivo 169 
comparison of the pharmacodynamic targets for echinocandin drugs against Candida 170 
species. Antimicrob Agents Chemother 54:2497–506. 171 
7.  Bellmann R, Smuszkiewicz P. 2017. Pharmacokinetics of antifungal drugs: practical 172 
implications for optimized treatment of patients. Infection 45:737–779. 173 
8.  Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. 2004. Population 174 
pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 175 
 9 
44:590–598. 176 
9.  Liu P. 2013. Population Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in 177 
Adult Patients with Fungal Infections. Antimicrob Agents Chemother 57:466–474. 178 
10.  Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell 179 
DN, Gumbo T, Drusano GL, Walsh TJ. 2007. Population Pharmacokinetics of Micafungin 180 
in Pediatric Patients and Implications for Antifungal Dosing. Antimicrob Agents Chemother 181 
51:3714–3719. 182 
11.  Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A, Fuller J, 183 
Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Ostrosky-184 
Zeichner L, Pelaez T, St-Germain G, Turnidge J. 2014. Multicenter study of anidulafungin 185 
and micafungin MIC distributions and epidemiological cutoff values for eight Candida 186 
species and the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 187 
58:916–22. 188 
 189 
 190 
 191 
 192 
 193 
 194 
 195 
 196 
 197 
 198 
 199 
 200 
 10 
Table 1. Population pharmacokinetic parameters of anidulafungin  201 
 202 
Parameter
 a
 (Units)  Median  Mean 95% Credibility limits  Standard Deviation 
CL1 (L/h/70kg) 0.936  0.852 0.862-0.987 0.199 
V (L)  16.275  18.413 9.735-27.223 10.199 
Kcp (h
-1
)  0.702  2.0417 0.222-2.179 3.028 
Kpc (h
-1
)  0.394  0.951 0.083-0.905 1.142 
 203 
a
CL1: Clearance per 70kg so that CL=CL1* (Total Body Weight/70)**0.75); V: volume of the 204 
central compartment; Kcp and Kpc are the first-order intercompartmental rate constants. 205 
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Figure 1 221 
 222 
FIG 1. Anidulafungin concentration-time profile of patients receiving a loading dose of 200 mg i.v 223 
followed by a mantenaince dose of 100 mg q24h i.v.  Intensive sampling was performed after the 224 
third day of treatment. 225 
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Figure 2.  236 
 237 
 238 
FIG 2. Population (A) and individual (B) predicted minocycline concentrations vs. observed 239 
concentrations of minocycline.  The broken line is the line of identity (observed = predicted 240 
concentrations). 241 
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 254 
Figure 3.  255 
 256 
FIG 3. Visual predictive check of anidulafungin plasma concentrations versus time for the final 257 
model.  Gray shading shows the confidence bound around each simulated centile.  Open circles are 258 
the observed concentrations of anidulafungin. 259 
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 269 
Figure 4.  270 
 271 
 272 
 273 
FIG 4. PTA of anidulafungin for patients with different total body weights (70 and 150 kg) against 274 
C. albicans and C. glabrata and MIC distributions according to CLSI methodology (11) 275 
 276 
Table 1. Population pharmacokinetic parameters of anidulafungin  
 
Parameter a (Units)  Median  Mean 95% Credibility limits  Standard Deviation 
CL1 (L/h/70kg) 0.936  0.852 0.862-0.987 0.199 
V (L)  16.275  18.413 9.735-27.223 10.199 
Kcp (h-1)  0.702  2.0417 0.222-2.179 3.028 
Kpc (h-1)  0.394  0.951 0.083-0.905 1.142 
 
aCL1: Clearance per 70kg so that CL=CL1* (Total Body Weight/70)**0.75); V: volume 
of the central compartment; Kcp and Kpc are the first-order intercompartmental rate 
constants. 
 




